Enanta is a clinical stage biotechnology company dedicated to creating oral drugs for viral infections. Our story began in 1995 when we grew from humble beginnings to the company we are today — one that collaborated with AbbVie to discover two protease inhibitor compounds that were each developed and commercialized as part of an AbbVie combination regimen for chronic hepatitis C virus (MAVYRET® and VIEKIRA PAK®, respectively). Currently, we have a diverse and robust pipeline, including one of the most advanced respiratory virology treatment portfolios in the industry, which we are progressing through clinical development with programs for respiratory syncytial virus, SARS-CoV-2 and human metapneumovirus. We are also advancing a clinical stage program for a combination treatment for chronic hepatitis B virus infection.